Kalray Wins Flash Memory Summit Award for the Second Year in a Row
10.8.2023 17:48:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software technologies and solutions for the high-performance, data-centric computing and storage markets, has been recognized as the leader of the DPU category in the 17th Annual Flash Memory Summit Awards competition.
Flash Memory Summit (FMS) is the world’s largest international comprehensive memory and storage showcase, hosted at the Santa Clara Convention Center, California, USA. The new Kalray K220-LP Storage Acceleration Card, powered by Kalray's 3rd generation DPU processor, won the FMS Award in the DPU category. This Flash Memory Summit Award symbolizes the industry's acknowledgment of the innovation and business value that Kalray solutions bring to the market.
KALRAY UNVEILS ITS NEW K220-LP™ SMART STORAGE ACCELERATOR
Kalray’s K220-LP™ Smart Storage Accelerator (SSA) was introduced at FMS this year, bringing storage offload to the next level. By offloading intensive storage data services from the main CPU, the SSA releases all the potential of NVMe SSDs in any server with local NVMe devices. The main CPU is freed to perform billable tasks while all storage-related tasks are offloaded to the Kalray K220-LP™ Smart Storage Accelerator.
“Customers have a need to maximize their server investments by pursuing greater optimization and performance. This can be achieved by offloading storage data services to specialized processors for maximum ROI of the server infrastructure,” said Jay Kramer, chairman of the awards program and president of Network Storage Advisors Inc. “We are proud to recognize Kalray’s Smart Storage Accelerators for their ability to efficiently store both data and metadata on storage class memory (SCM) while offloading storage data services and applications from the main CPU. This solution enables customers to realize the full potential of local NVMe SSDs deployed in any industry-standard server.”
KALRAY DEMONSTRATES THAT QLC MEMORY ADOPTION BENEFITS DATA CENTERS
As a powerful use case, Kalray demonstrated how its solution allows a new generation of SSDs, called QLC SSDs, to be adopted into data centers without requiring any changes to the data center operating system, file system, or applications. Kalray DPUs have accelerators, fast coherent memory, and flexible programmability, which makes them ideal for storage management functions such as managing new QLC technology. Thanks to Kalray’s solution, data centers can take full advantage of the price, capacity, and performance benefits of QLC flash devices. The result is a data center that realizes the benefits of QLC without performance and durability penalties and without the need to modify existing software.
“QLC SSDs present great economic advantages by delivering greater capacity and density. But compared to other SSD types, QLC technology has challenges to overcome, including lower endurance, higher latency, and reduced performance under heavy workloads,” added Jay Kramer. “We are proud to recognize Kalray’s Smart Storage Accelerators for their highly effective performance in enabling a simple deployment on industry-standard servers. This solution allows customers to achieve cost and capacity benefits of QLC devices transparently, with no hardware architectural changes and no software stack changes.”
ACKNOWLEDGEMENT OF THE SOLUTION’S INNOVATION
“It is a great honor to win a Flash Memory Summit award for the second year in a row,” said Éric Baissus, chief executive officer of Kalray. “This award represents strong recognition of the value of our solutions. Customers who integrate our new K220-LP™ SSA into their servers can accelerate the transition from traditional storage architectures relying on SAS (Serial Attached SCSI) to high-performance, power-efficient NVMe-based solutions.”
The K220-LP™ solution includes Kalray’s AccessCore® Storage (ACS) software SDK. Thanks to ACS SDK, the K220-LP™ SSA is fully programmable, enabling offload of custom storage or computational application processing, thus removing the usual bottlenecks of traditional architectures. The Kalray solution enables data centers to leapfrog outdated technologies that are unable to sustain the storage requirements of demanding workloads and embrace the benefits of modern, scalable, and flexible data solutions with minimal effort.
This is the second consecutive award Kalray has received from Flash Memory Summit, maintaining momentum in innovation following last year’s award for most innovative technology with Flashbox™.
ABOUT KALRAY
Kalray (Euronext Growth Paris – FR0010722819 – ALKAL) is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures.
Kalray’s offerings include unique patented DPU (Data Processing Unit) processors and acceleration cards, as well as leading-edge software-defined storage and data management solutions. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers and to design the best solutions in fast-growing sectors such as AI, media & entertainment, life science, scientific research, edge computing, automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. Visit us at www.kalrayinc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809063602/en/
Contact information
INVESTORS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Tel. 04 76 18 90 71
ACTUS finance & communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Tel. 01 53 67 36 72
PRESS
Diana EADINGTON
communication@kalrayinc.com
Tel. +44 7939 877 880
ACTUS finance & communication
Serena BONI
sboni@actus.fr
Tel. 04 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
